SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Injective taken over by the community.

Nonja

The Nonja ($NONJA.X) community is actively rallying behind the token as a high-beta, leverage-style play on the Injective ($INJ.X) ecosystem, driven by strong sentiment regarding the chain's institutional adoption and recent tokenomics updates. Holders are highly focused on the project's burned liquidity as a rug-protection feature and are positioning for potential exponential gains as broader market interest in Injective's fundamental growth continues to build.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

Hyperliquid Strategies Inc. is seeing significant momentum as investors pivot toward its unique treasury model, which holds a substantial position in the HYPE token. The community is actively discussing the stock's potential for a squeeze driven by institutional interest, heavy volume, and the ongoing integration of perpetual trading infrastructure into traditional markets.

TKO Group Holdings, Inc. engages in the provision of sports and entertainment. It operates through the following segments: Ultimate Fighting Championship (UFC), World Wrestling Entertainment (WWE), and IMG. The UFC segment refers to a global sports brand and media content company. The WWE segment is involved in media organizations and global leaders in sports entertainment. The IMG segment manages the operations of the IMG business and on location. The company was founded on March 29, 2023 and is headquartered in New York, NY.

TKO Group Holdings Inc - Ordinary Shares - Class A

TKO GROUP HLDGS INC

TKO is currently a major point of discussion due to the historic scheduling of a high-profile UFC event at the White House, fueling debate among investors about the event's commercial viability and potential financial impact. Simultaneously, the community is actively debating the stock's long-term valuation and structural health, with some market participants highlighting institutional accumulation and S&P 500 inclusion, while others express concerns over content strategy and accounting practices.

Veeva Systems, Inc. engages in the provision of industry cloud solutions for the global life sciences industry. The firm's solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance. Its customer relationship management solutions enable its customers to increase the productivity and compliance of their sales and marketing functions. The firm's regulated content management and collaboration solutions enable its customers to more efficiently manage regulated, content-centric processes across the enterprise. Its customer master solution enables customers to more effectively manage complex healthcare provider and healthcare organization data. The company was founded by Mark Armenante, Peter P. Gassner, Doug Ostler, Mitch Wallace and Matthew J. Wallach on January 12, 2007 and is headquartered in Pleasanton, CA.

Veeva Systems Inc - Ordinary Shares - Class A

Veeva Systems is drawing significant investor attention due to its strong economic moat in life sciences software and the strategic integration of AI to drive operational efficiencies. While some market participants debate the competitive landscape following the company's separation from Salesforce, others view the stock as a compelling long-term opportunity, particularly as it continues to win major biopharma contracts and benefits from its recent inclusion in the S&P 500.

Zoracles

Zoracles is seeing active community discussion as traders monitor its price action relative to broader crypto market volatility and upcoming ecosystem catalysts. Many investors are currently focused on potential accumulation opportunities, debating whether the token is undervalued while waiting for technical indicators to signal a reversal.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending following the publication of positive Phase 3 results for daraxonrasib in metastatic pancreatic cancer, which demonstrated an unprecedented improvement in overall survival compared to standard chemotherapy. While the community is actively discussing the potential for a major buyout or expedited FDA approval, sentiment remains focused on the drug's role as a potential new standard of care in a difficult-to-treat disease.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its identity as a culture-first cryptocurrency on Solana, emphasizing cannabis education and long-term community building ahead of 4/20. Discussions are heavily focused on its 'Weedcoin OG' strain, its mission to challenge traditional pharmaceutical models, and active community efforts to maintain engagement through scavenger hunts and social media spaces.

Pool Corp. engages in the wholesale distribution of swimming pool supplies, equipment, and related leisure products. It also offers non-discretionary pool maintenance products such as chemicals and replacement parts, discretionary products like packaged pool kits, whole goods, irrigation, and landscape products, including a complete line of commercial and residential irrigation products and parts, power equipment for the professional landscape market, specialty products such as outdoor lighting, grills, and outdoor kitchen components, and golf irrigation and water management products. The company was founded in 1993 and is headquartered in Covington, LA.

Pool Corporation

Pool Corporation is trending as investors weigh the impact of higher interest rates on new pool construction and consumer discretionary spending against potential buying opportunities following a significant decline in share price. The community is actively debating whether current valuation levels offer an attractive entry point for long-term growth or if continued macro headwinds pose further downside risks.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as investors closely monitor clinical developments for ivonescimab, particularly following its selection for a prestigious ASCO plenary session which has sparked optimism over its potential to challenge industry benchmarks. The community remains hyper-focused on upcoming regulatory milestones and ongoing trial data, fueling active debates around the company's valuation, potential partnership opportunities, and its long-term competitive position in the oncology space.

Lattice Semiconductor Corp. engages in the business of developing technologies that are monetized through differentiated programmable logic semiconductor products, system solutions, design services, and licenses. It also offers silicon-based and silicon-enabling products, evaluation boards, development hardware, and related intellectual property licensing, services, and sales. The company was founded in 1983 and is headquartered in Hillsboro, OR.

Lattice Semiconductor Corp.

Lattice Semiconductor (LSCC) is gaining significant traction as investors pivot toward foundational edge AI and security hardware. The stock is currently hitting new 52-week highs, driven by community enthusiasm surrounding its strategic role in the AI robotics ecosystem and strong institutional rotation into premium AI-focused silicon.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026 Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on...

Joanne Donovan Sells 50,000 Shares of Edgewise Therapeutics (NASDAQ:EWTX) Stock

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) CMO Joanne Donovan sold 50,000 shares of the firm's stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $38.57, for a total transaction of $1,928,500.00. Following the completion of the transaction, the...

Edgewise Therapeutics (NASDAQ:EWTX) CMO Sells $163,646.70 in Stock

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) CMO Joanne Donovan sold 5,230 shares of the firm's stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $31.29, for a total value of $163,646.70. Following the sale, the chief marketing officer owned...

CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics?

Equity

The company said Aficamten for patients with symptomatic non-obstructive hypertrophic cardiomyopathy met both primary endpoints.

Edgewise Therapeutics (NASDAQ:EWTX) Sets New 52-Week High  - Should You Buy?

Edgewise Therapeutics (NASDAQ:EWTX) Hits New 1-Year High - Time to Buy...

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire BOULDER...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by Analysts

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine analysts that are presently covering the company, MarketBeat.com...

Edgewise Therapeutics (EWTX) to Release Earnings on Thursday

Edgewise Therapeutics (NASDAQ:EWTX) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...

Moody Aldrich Partners LLC Has $1.07 Million Holdings in Edgewise Therapeutics, Inc. $EWTX

Moody Aldrich Partners LLC cut its stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 48.0% in the fourth quarter, according to the company in its most recent filing with the...

Edgewise Therapeutics (NASDAQ:EWTX) Sees Large Volume Increase - Here's What Happened

Edgewise Therapeutics (NASDAQ:EWTX) Sees Large Volume Increase - Should You Buy...

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

EWTX
Edgewise Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest EWTX News

EWTXEdgewise Therapeutics Inc